Whitehawk Therapeutics, Inc. (WHWK): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Whitehawk Therapeutics, Inc. (WHWK) filed an SEC Form 8-K — Results of Operations and Financial Condition. PRESS RELEASE Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cash equivalents and short-term investments b

Biocytogen (SSE:688796; HKEX:02315) and Whitehawk Therapeutics (Nasdaq:WHWK) announced a global collaboration to develop bispecific antibody-drug conjugates. Biocytogen will supply up to five bispecific antibodies via its RenLite platform; Whitehawk will evaluate them with its ADC linker-payload tech and may advance candidates. Biocytogen expects upfront, milestones, and low single-digit royalties.

Halozyme Therapeutics (HALO) priced a $1.3B upsized offering of 1.50% convertible senior notes due 2033, with a 13-day option for additional $200M. Notes have an initial conversion price of $139.84, a 27.5% premium over the closing price. Proceeds (~$1.275B) will fund capped call transactions, repurchase existing notes, and general corporate purposes. The company expects to close the offering on September 22, 2026.

Corteva is defending its planned split into two companies, Corteva and Vylor, against a legal challenge from 21 states. The states argue the split could hinder PFAS liability claims, but Corteva denies wrongdoing and asserts the separation is strategic. Corteva plans to keep its headquarters in Indianapolis, while Vylor will be based in Iowa. The court will decide if the split can proceed as scheduled on Oct. 1.

CoreWeave plans a $3B convertible debt sale, with an option for an additional $500M. The company also authorized an at-the-market share sale of up to 35M shares. Proceeds will fund AI compute infrastructure and offset dilution. In Q3, CoreWeave signed deals for compute capacity at an annualized rate of $40M per megawatt, increasing its contracted power capacity to 4.2 gigawatts.

Silver Lake Group acquired 42.8M shares of Dell Technologies (DELL) at $535.25 per share, representing 83.34% of its portfolio. Dell's stock has surged 360.41% year-to-date, but GuruFocus values it at $229.11, indicating significant overvaluation. The company's financial health shows mixed metrics, with strong growth but negative gross margin growth.